An observational cohort study on the incidence of SARS-CoV-2 infection and B.1.1.7 variant infection in healthcare workers by antibody and vaccination status
Year: 2021
Type: preprint
Study design: Observational Study
Abstract: Background Natural and vaccine-induced immunity will play a key role in controlling the SARS-CoV-2 pandemic. SARS-CoV-2 variants have the potential to evade natural and vaccine-induced immunity. Methods In a longitudinal cohort study of healthcare workers (HCWs) in Oxfordshire, UK, we investigated the protection from symptomatic and asymptomatic PCR-confirmed SARS-CoV-2 infection conferred by vaccination (Pfizer-BioNTech BNT162b2, Oxford-AstraZeneca ChAdOx1 nCOV-19) and prior infection (determined using anti-spike antibody status), using Poisson regression adjusted for age, sex, temporal changes in incidence and role. We estimated protection conferred after one versus two vaccinations and from infections with the B.1.1.7 variant identified using whole genome sequencing. Results 13,109 HCWs participated; 8285 received the Pfizer-BioNTech vaccine (1407 two doses) and 2738 the Oxford-AstraZeneca vaccine (49 two doses). Compared to unvaccinated seronegative HCWs, natural immunity and two vaccination doses provided similar protection against symptomatic infection: no HCW vaccinated twice had symptomatic infection, and incidence was 98% lower in seropositive HCWs (adjusted incidence rate ratio 0.02 [95%CI <0.01-0.18]). Two vaccine doses or seropositivity reduced the incidence of any PCR-positive result with or without symptoms by 90% (0.10 [0.02-0.38]) and 85% (0.15 [0.08-0.26]) respectively. Single-dose vaccination reduced the incidence of symptomatic infection by 67% (0.33 [0.21-0.52]) and any PCR-positive result by 64% (0.36 [0.26-0.50]). There was no evidence of differences in immunity induced by natural infection and vaccination for infections with S-gene target failure and B.1.1.7. Conclusion Natural infection resulting in detectable anti-spike antibodies and two vaccine doses both provide robust protection against SARS-CoV-2 infection, including against the B.1.1.7 variant. Summary Natural infection resulting in detectable anti-spike antibodies and two vaccine doses both provided ≥ 85% protection against symptomatic and asymptomatic SARS-CoV-2 infection in healthcare workers, including against the B.1.1.7 variant. Single dose vaccination reduced symptomatic infection by 67%.
Source: medRxiv
Authors: Sheila F Lumley, Gillian Rodger, Bede Constantinides, Nicholas Sanderson, Kevin K Chau, Teresa L Street, Denise O’Donnell, Alison Howarth, Stephanie B Hatch, Brian D Marsden, Stuart Cox, Tim James, Fiona Warren, Liam J Peck, Thomas G Ritter, Zoe de Toledo, Laura Warren, David Axten, Richard J Cornall, E Yvonne Jones, David I Stuart, Gavin Screaton, Daniel Ebner, Sarah Hoosdally, Meera Chand, Derrick W Crook, Anne-Marie O’Donnell, Christopher P Conlon, Koen B Pouwels, A Sarah Walker, Tim EA Peto, Susan Hopkins, Timothy M Walker, Nicole E Stoesser, Philippa C Matthews, Katie Jeffery, David W Eyre
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Keywords: SARS-CoV-2, COVID-19 pandemic, healthcare workers, B.1.1.7 variant, Omicron variant, vaccine-induced immunity, natural immunity, anti-spike antibodies, BNT162b2, ChAdOx1 nCoV-19 vaccine, vaccine dose number, S-gene target failure, symptomatic infection, asymptomatic infection, infection incidence
Open Access status: green
Funders: Pfizer, Genome Canada, Merck KGaA, Wellcome Trust, Ontario Genomics, European Federation of Pharmaceutical Industries and Associations, Robertson Foundation, Government of the United Kingdom, Kennedy Trust for Rheumatology Research, National Institute for Health Research Health Protection Research Unit, Ontario Genomics Institute, National Institute for Health and Care Research, Department of Health and Social Care, University of Oxford, Fundação de Amparo à Pesquisa do Estado de São Paulo, Public Health England, Huo Family Foundation, Novartis Pharma, Medical Research Council
Awards: G1188516431, G1485802007, Structural studies of viruses and their interactions with cells, G2027436598, G2309620997, G2939136323, G3309060605, G4952940486, Structural Studies on Viruses, Viral Proteins and Cell Interactions, G556617960, How do people get multi-drug resistant tuberculosis?, G6010844705, G6649613551, G6688990311, G6817511090, G6868616705, G7428214171, G7669079602, G774547617, Defining host and viral factors that are associated with hepatitis B virus control and clearance in Caucasian and African adults., G7959052343, G8140873135, G8348572397
OpenAlex ID: W6939205471
